DETROIT--(BUSINESS WIRE)--Asterand plc (LSE:ATD), is pleased to report the announcement by BTG (2nd April 2009) that BGC20-1531, a novel EP4 receptor antagonist for the treatment of migraine headaches, is planned to enter Phase IIa studies in H2 2009 with data anticipated in H2 2010. If clinical proof of principle is demonstrated in these studies, BTG will seek development partners to conduct Phase IIb and subsequent studies.
